Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Article content
CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment.
Article content
Article content
'We have taken careful steps to evaluate all aspects of our business to ensure continued value generation, and this out-licensing agreement with DCx for our discovery platforms enables us to further focus on our clinical portfolio and drive cost reductions while maintaining an economic interest in the platform technologies we have developed,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'We look forward to reporting initial data from our two ongoing Phase 1 clinical trials in the second half of 2025, and continue to evaluate partnering and strategic alternatives across our portfolio assets.'
Article content
Under the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% common equity position in DCx (including certain dilution protection rights) and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low-single digit tiered sales royalties for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare's preclinical research employees. Repare has the right to appoint one nominee to the board of directors of DCx. In connection with the transaction, Repare out-licensed its clinically-validated SNIPRx platform and its early discovery-stage SNIPRx-surf and STEP 2 platforms, along with other intellectual property. The SNIPRx-surf platform identifies cell surface targets based on gene expression and protein features in tumors or cancer models, including by clinically relevant biomarkers and machine learning algorithm. The STEP 2 platform is a chemogenomic discovery platform, which uses CRISPR-enabled genetic screens with small molecule inhibitors to identify clinically relevant genetic lesions that are sensitive to small molecule inhibitors.
Article content
About Repare Therapeutics Inc.
Article content
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare has utilized its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Repare's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
Article content
DCx Biotherapeutics is a preclinical-stage discovery and translational company addressing key dependencies of cancer lesions by developing multi-modal synergistic-targeting therapeutics with improved efficacy and tolerability while minimizing resistance. DCx's MuSic™ platform is enabled through the integration of CRISPR-based high-throughput functional screening combined with deep bioinformatics in support of advancing a pipeline of immune-stimulatory precisiono0 antibody drug conjugates to improve therapeutic outcomes against genetically-defined cancers. Visit www.dcxbio.com to learn more.
Article content
Forward-Looking Statements
Article content
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: Repare's out-license of its discovery platform to DCx; the risk that Repare may not realize the potential benefits of the transaction with DCx; Repare's ability to drive cost reductions while maintaining an economic interest in its assets; the timing, progress and results of Repare's two ongoing Phase 1 clinical trials; and the receipt of milestone payments and royalties under the out-license agreement. These forward-looking statements are based on Repare's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Repare's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and changes in tariffs and trade policies, on Repare's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Repare's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Repare's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in Repare's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025. Repare expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at .
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
25 minutes ago
- Toronto Sun
GOLDSTEIN: Carney can't fix Canada's underperforming economy on his own
Get the latest from Lorrie Goldstein straight to your inbox Prime Minister Mark Carney delivers a press conference at Rideau Hall after his cabinet's swearing-in ceremony on May 13, 2025 in Ottawa. Photo by Andrej Ivanov / Getty Images Prime Minister Mark Carney's pledge to make the Canadian economy the strongest in the G7 is the equivalent of attempting to turn around the Titanic before it hits the iceberg. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account An indication of the enormity of this task is to look at the performance of the G7 countries in real Gross Domestic Product (GDP) per capita, which measures economic output per person, adjusted for inflation, and is a widely accepted metric of a nation's prosperity and standard of living. Low economic growth as measured by real GDP per capita has been a longstanding problem in Canada. Under Carney's predecessor, Justin Trudeau (who appointed Carney to chair his economic growth task force in September 2024), Canada recorded the worst record of economic growth since the government of R.B. Bennett in the depths of the Great Depression. According to Jake Fuss, director of fiscal studies for the Fraser Institute writing in The Hub last year, Canada's real GDP per capita grew by 1.9% in the Trudeau years. Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. That was lowest in the G7, which includes the U.K., Germany, France, Italy, Japan and, most alarmingly, the U.S., our largest trading partner, where real GDP per capita grew by 14.7% during the same period. University of Calgary economist Trevor Tombe, also writing in The Hub last year, noted real GDP per capita in the U.S. is now almost 50% higher than in Canada – unprecedented in modern history. Read More In the Liberals' 2022 budget, then-finance minister Chrystia Freehand warned that unless this trend is reversed, 'the Organization for Economic Co-operation and Development projects that Canada will have the lowest per-capita GDP growth rate among its (38) member countries' from 2020 to 2060. This advertisement has not loaded yet, but your article continues below. Carney's announcement of proposed legislation on Friday – which he wants passed before Parliament adjourns from the summer – to reduce federal barriers to interprovincial trade, increase labour mobility and streamline government approvals for nation building infrastructure projects, are all aimed at increasing economic growth. But they all depend on co-operation by and among the provinces. And the reality is that decades of inaction on these issues has cost the Canadian economy an estimated $200 billion annually, increased the cost of goods and services to Canadians by up to 14.5% and reduced GDP growth by up to 8% annually. At the meeting between Carney and Canada's premiers and territorial leaders last week in Saskatoon to address these issues in the face of the threat posed to the Canadian economy by U.S. President Donald Trump's tariffs, all the participants paid lip service to working together on these issues. This advertisement has not loaded yet, but your article continues below. A supply depot servicing the Keystone XL crude oil pipeline lies idle in Oyen, Alta., Feb. 1, 2021. Photo by Todd Korol / REUTERS / FILES But the one premier not present – B.C.'s David Eby, who was on a trade mission to Asia – promptly rejected any new pipeline crossing his province's territory, as did many Quebec politicians when it comes to their province. Any new pipelines will also be opposed by environmental organizations and some (although not all) Indigenous groups who, while they do not have veto power over such projects, must be meaningfully consulted under Canadian law. Alberta Premier Danielle Smith has cited the enormous economic damage caused by Canada's failure to build pipelines. Had the Northern Gateway, Energy East and Keystone pipelines been built (Keystone was killed by then-U.S. president Barack Obama), she said, Canada would be producing 2.5 million more barrels of oil per day. This advertisement has not loaded yet, but your article continues below. 'That's $55 billion a year worth of GDP value, which is worth $17 billion to my government alone and about an equal amount to the federal government.' RECOMMENDED VIDEO The Carney government does have more direct control of some issues it can move on to boost Canada's economic growth. For example, it can introduce taxation policies that encourage businesses to invest in new technologies that boost productivity, as well as increase competition. It can lower Canada's immigration levels so that increases in population do not exceed the rate of economic growth, which reduces GDP per capita. It can reduce government spending. On that issue, Carney says he intends to reduce the growth rate in the operational costs of the federal government under Trudeau from 9% annually to less than 2%. But Carney's election campaign platform also outlined $130 billion in new spending over four years with total deficits of $224.8 billion. While Carney says most of that will be spent on infrastructure, it's 71% higher than the $131.4 billion in deficit spending the Trudeau government predicted during the same period in its fall economic statement in December 2024. Finally, of course, Carney needs to negotiate a deal on tariffs with Trump. lgoldstein@ Olympics Sunshine Girls NHL Ontario Sunshine Girls
Edmonton Journal
an hour ago
- Edmonton Journal
U.S. ambassador says Canadians facing device searches, detainment 'not a pattern'
Article content OTTAWA — The American ambassador to Canada is pushing back on Ottawa's travel advice, saying his country doesn't search phones at the border and arguing some Americans travelling here are having a tough time. 'We welcome Canadians to come in and invest, to spend their hard-earned Canadian dollars at U.S. businesses,' U.S. Ambassador Pete Hoekstra told The Canadian Press in an interview Friday.
Vancouver Sun
an hour ago
- Vancouver Sun
Marc Garneau left lasting legacy on Earth and in space, former colleagues say
MONTREAL — Canadian scientists working on asteroid missions, exploring the universe through the James Webb Space Telescope or helping to put rovers on Mars say they can in some way thank Marc Garneau, who left an enduring legacy both as an astronaut and head of the country's space agency. While best-known in later years as a federal cabinet minister, Garneau, who died this week at 76, was also a Navy officer, a systems engineer, and an astronaut with a lifelong passion for science, according to his friends and colleagues. In 1984, he made history as the first Canadian in space when he served as a payload specialist aboard the Space Shuttle Challenger. He returned to space twice more, in 1996 and 2000, before serving as the president of the Canadian Space Agency from 2001 to 2005. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. 'All his life was devoted to public service,' said Gilles Leclerc, an ex-CSA official who worked with him. 'And he was really a role model to all the Canadian astronauts who came after him.' As CSA president, Garneau laid the building blocks for the space exploration program that would bring together other initiatives previously developed separately, Leclerc said. He was also 'ahead of his time' when it came to being conscious of the environment and understanding the importance of applying space technology for practical uses such as satellite communications. 'During his tenure, he really wanted us to focus more on science: astronomy, planetary science, lunar exploration,' Leclerc said in a phone interview. 'So all these things that now we see, all these missions that Canada participated in, like a mission to the asteroids, two missions to Mars, the James Webb Space Telescope…Marc had a real strong influence in shaping the future of the space program for a long time.' On Friday, CSA President Lisa Campbell paid tribute to Garneau, who she called a 'cherished member of the space agency family.' 'We remain deeply grateful for his extraordinary public service and enduring contributions to Canada and the world, from making history as the first Canadian in space to guiding the Canadian Space Agency as its president,' she said at an event at the agency's Montreal-area headquarters. 'his integrity, his generosity of spirit touches everyone who had the privilege of working with him.' Flags at government buildings in Montreal have been lowered to half-mast in tribute. Garneau would carry his love of science — as well as his significant technical knowledge — into his next role as a politician, according to his former chief of staff and close personal friend. Marc Roy said Garneau decided to run for office out of a desire to give back after his successful space career. Garneau often spoke about how seeing the Earth from above 'changed his perspective on many things,' including conflicts and environmental protections, Roy said. 'So many things that unfortunately divide us as humans that become so irrelevant when you look at our world from abroad,' Roy said in a phone interview. 'And that desire to want to contribute at an even higher level, at a different, at a policy level, at a governance level is what inspired him to run for federal politics.' Garneau was elected as MP in Notre-Dame-de-Grace_Westmount in 2008 after failing to win another Montreal-area seat in 2006. Roy said Garneau's scientific background shone through most clearly as Transport minister, when he was able to instantly grasp technical briefings on ships, planes and trains. Above all, his history as a naval officer and astronaut gave him a laser focus on safety, Roy said, in a role that would see Garneau introduce measures including the safer skies initiative, and the oceans protection plan to monitor ship traffic, oil spills and wildlife. Roy said Garneau often spoke about the weight of the portfolio, 'wanting to ensure that he did it to the best of his ability, that he truly understood every decision that he was taking and every decision that was possible for him to make in order to ensure the safety of the traveling public and the safety overall of our trade and transportation corridors.' Roy said Garneau brought a scientist's analytic, 'Spock-like' demeanor to his roles. But he said some of the issues Garneau championed most passionately were social causes, including serving as a joint chair of the special joint committee on medical assistance in dying. And, despite his considerable intelligence, Roy said Garneau remained humble. 'He had a very rare quality in a politician, from his very debut until the very last day before he retired as member of Parliament, which was: he listened more than he talked,' Roy said. He said his friend was diagnosed only months ago with two cancers: leukemia and lymphoma, and died after a battle that was 'brave but short.' Roy said his friend's time since retirement was spent enjoying time with his wife, Pam, and his children, and completing work on his autobiography, 'A Most Extraordinary Ride: Space, Politics and the Pursuit of a Canadian Dream.' Roy said the book gave Garneau closure. 'He wanted to tell the story that, 'I'm just like everybody else and I failed and I've screwed up and I pulled up my socks and I learned from my mistakes and I moved on,'' Roy said. 'And that was very important for him to tell that story, and I'm just so fortunate that he had the time to do that.' Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here .
